ブピバカインリポソーム注射懸濁液の世界市場2020-2026:20ml、10ml

QYResearchが発行した調査報告書(QYR20AP00408)
◆英語タイトル:Global Bupivacaine Liposome Injectable Suspension Industry Research Report, Growth Trends and Competitive Analysis 2020-2026
◆商品コード:QYR20AP00408
◆発行会社(リサーチ会社):QYResearch
◆発行日:2020年3月(※2024年版があります。お問い合わせください。)
◆ページ数:113
◆レポート形式:英語 / PDF
◆納品方法:Eメール(受注後3営業日)
◆調査対象地域:グローバル
◆産業分野:製薬・医療
◆販売価格オプション(消費税別)
Single User(1名様閲覧用)USD4,900 ⇒換算¥725,200見積依頼/購入/質問フォーム
Multi User(5名様閲覧用)USD7,350 ⇒換算¥1,087,800見積依頼/購入/質問フォーム
Enterprise License(同一法人内共有可)USD9,800 ⇒換算¥1,450,400見積依頼/購入/質問フォーム
販売価格オプションの説明はこちらでご利用ガイドはこちらでご確認いただけます。
※お支払金額は「換算金額(日本円)+消費税+配送料(Eメール納品は無料)」です。
※本体価格が¥30,000未満のレポートにつきましては、ハンドリングチャージ¥5,000が別途かかります。
※Eメールによる納品の場合、通常ご注文当日〜2日以内に納品致します。
※レポート納品後、納品日+5日以内に請求書を発行し、お客様宛に郵送いたしますので、請求書発行日より2ヶ月以内に銀行振込にて支払をお願いします。
※上記の日本語題名はH&Iグローバルリサーチが翻訳したものです。英語版原本には日本語表記はありません。
※為替レートは適宜修正・更新しております。リアルタイム更新ではありません。
※弊社H&Iグローバルリサーチ株式会社はQYResearch社の日本における正規代理店です。同社発行の市場リサーチレポート及びリサーチサービスに関するお問い合わせは弊社までお願い致します。QYResearch社の概要及び新刊レポートはこちらでご確認いただけます。

当リサーチレポートでは、ブピバカインリポソーム注射懸濁液の世界市場規模が2019年xx百万ドルから2026年xx百万ドルまで年平均xx%成長すると予測しています。当レポートは、ブピバカインリポソーム注射懸濁液のグローバル市場動向、メーカー別競争状況、種類別市場規模(20ml、10ml)、用途別市場規模(獣医、人間)、北米市場、アジア市場、中南米市場、中東・アフリカ市場分析、関連企業情報、サプライチェーン、販売チャネル分析、地域別市場規模予測データなどを掲載しています。

・レポート概要
・グローバル市場動向
・メーカー別競争状況
・ブピバカインリポソーム注射懸濁液の種類別市場2015-2026:20ml、10ml
・ブピバカインリポソーム注射懸濁液の用途別市場2015-2026:獣医、人間
・ブピバカインリポソーム注射懸濁液の北米市場分析
・ブピバカインリポソーム注射懸濁液のアジア市場分析
・ブピバカインリポソーム注射懸濁液の中南米市場分析
・ブピバカインリポソーム注射懸濁液の中東・アフリカ市場分析
・関連企業情報:Pacira Pharmaceuticals
・サプライチェーン及び販売チャネル分析
・地域別市場規模予測2021-2026:北米、ヨーロッパ、アジア、中南米、中東・アフリカ
・結論
【レポートの概要】

Liposomal bupivacaine has been approved by the US Food and Drug Administration for local infiltration for pain relief after bunionectomy and hemorrhoidectomy. In 2019, the global Bupivacaine Liposome Injectable Suspension market size was US$ xx million and is forecast to US$ xx million in 2026, growing at a CAGR of xx% during the forecast period. In this study, 2019 has been considered as the base year and 2020 to 2026 as the forecast period to estimate the market size for Bupivacaine Liposome Injectable Suspension.
The market research report offered here is a very useful resource that can help manufacturers, stakeholders, decision-makers, and other market participants to become familiar with every factor impacting the growth of the global Bupivacaine Liposome Injectable Suspension market. The analysts authoring the report have closely studied key strategies adopted by top players of the global Bupivacaine Liposome Injectable Suspension market. The report includes SWOT, and other market analyses to provide a clear and deep understanding of important aspects of the global Bupivacaine Liposome Injectable Suspension market. Readers of the report can become informed about current and future trends of the global Bupivacaine Liposome Injectable Suspension market and how they will impact market growth during the forecast period.
Geographic Segmentation
The report offers exhaustive assessment of different region-wise and country-wise Bupivacaine Liposome Injectable Suspension markets such as U.S., Canada, Germany, France, U.K., Italy, Russia, China, Japan, South Korea, India, Australia, Taiwan, Indonesia, Thailand, Malaysia, Philippines, Vietnam, Mexico, Brazil, Turkey, Saudi Arabia, U.A.E etc.
For the period 2015-2026, the report provides country-wise revenue and volume sales analysis and region-wise revenue and volume analysis of the global Bupivacaine Liposome Injectable Suspension market. For the period 2015-2020, it provides sales (consumption) analysis and forecast of different regional markets by Application as well as by Type in terms of volume.
Market Segmentation by Type and by Application
The report includes a detailed analysis of leading and by Type and by Application segments of the global Bupivacaine Liposome Injectable Suspension market. All of the segments covered in the report are broadly analyzed based on some deciding factors. The segmental analysis section of the report offers revenue, sales analysis and forecast of the global Bupivacaine Liposome Injectable Suspension market by Type and by Application segment for the period 2015-2026.

Market Segment by Type, the Bupivacaine Liposome Injectable Suspension market is segmented into
20ml
10ml

Market Segment by Application, the Bupivacaine Liposome Injectable Suspension market is segmented into
Veterinary
Human

This report includes the following manufacturers; we can also add the other companies as you want.
Pacira Pharmaceuticals

The study objectives are:
To analyze and research the global Bupivacaine Liposome Injectable Suspension status and future forecast, involving capacity, production, value, consumption, growth rate (CAGR), market share, historical and forecast.
To present the key Bupivacaine Liposome Injectable Suspension manufacturers, capacity, production, revenue, market share, and recent development for key players.
To split the breakdown data by regions, type, companies and applications.
To analyze the global and key regions market potential and advantage, opportunity and challenge, restraints and risks.
To identify significant trends, drivers, influence factors in global and regions.
To analyze competitive developments such as expansions, agreements, new product launches, and acquisitions in the market.

In this study, the years considered to estimate the market size of Bupivacaine Liposome Injectable Suspension are as follows:
History Year: 2015-2020
Base Year: 2019
Estimated Year: 2020
Forecast Year 2020 to 2026

【レポートの目次】

Table of Contents

1 Report Overview
1.1 Research Scope
1.2 Top Bupivacaine Liposome Injectable Suspension Manufacturers Covered: Ranking by Revenue
1.3 Market Segment by Type
1.3.1 Global Bupivacaine Liposome Injectable Suspension Market Size by Type: 2015 VS 2020 VS 2026 (US$ Million)
1.3.2 20ml
1.3.3 10ml
1.4 Market Segment by Application
1.4.1 Global Bupivacaine Liposome Injectable Suspension Consumption by Application: 2015 VS 2020 VS 2026
1.4.2 Veterinary
1.4.3 Human
1.5 Study Objectives
1.6 Years Considered
2 Global Market Perspective
2.1 Global Bupivacaine Liposome Injectable Suspension Revenue (2015-2026)
2.1.1 Global Bupivacaine Liposome Injectable Suspension Revenue (2015-2026)
2.1.2 Global Bupivacaine Liposome Injectable Suspension Sales (2015-2026)
2.2 Bupivacaine Liposome Injectable Suspension Market Size across Key Geographies Worldwide: 2015 VS 2020 VS 2026
2.2.1 Global Bupivacaine Liposome Injectable Suspension Sales by Regions (2015-2020)
2.2.2 Global Bupivacaine Liposome Injectable Suspension Revenue by Regions (2015-2020)
2.3 Global Top Bupivacaine Liposome Injectable Suspension Regions (Countries) Ranking by Market Size
2.4 Bupivacaine Liposome Injectable Suspension Industry Trends
2.4.1 Bupivacaine Liposome Injectable Suspension Market Top Trends
2.4.2 Market Drivers
2.4.3 Bupivacaine Liposome Injectable Suspension Market Challenges
2.4.4 Porter’s Five Forces Analysis
2.4.5 Primary Interviews with Key Bupivacaine Liposome Injectable Suspension Players: Views for Future

3 Competitive Landscape by Manufacturers
3.1 Global Top Bupivacaine Liposome Injectable Suspension Manufacturers by Sales (2015-2020)
3.1.1 Global Bupivacaine Liposome Injectable Suspension Sales by Manufacturers (2015-2020)
3.1.2 Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Manufacturers (2015-2020)
3.1.3 Global 5 and 10 Largest Manufacturers by Bupivacaine Liposome Injectable Suspension Sales in 2019
3.2 Global Top Manufacturers Bupivacaine Liposome Injectable Suspension by Revenue
3.2.1 Global Bupivacaine Liposome Injectable Suspension Revenue by Manufacturers (2015-2020)
3.2.2 Global Bupivacaine Liposome Injectable Suspension Revenue Share by Manufacturers (2015-2020)
3.2.3 Global Bupivacaine Liposome Injectable Suspension Market Concentration Ratio (CR5 and HHI)
3.3 Global Top Manufacturers by Company Type (Tier 1, Tier 2 and Tier 3) (based on the Revenue in Bupivacaine Liposome Injectable Suspension as of 2019)
3.4 Global Bupivacaine Liposome Injectable Suspension Average Selling Price (ASP) by Manufacturers
3.5 Key Manufacturers Bupivacaine Liposome Injectable Suspension Plants/Factories Distribution and Area Served
3.6 Date of Key Manufacturers Enter into Bupivacaine Liposome Injectable Suspension Market
3.7 Key Manufacturers Bupivacaine Liposome Injectable Suspension Product Offered
3.8 Mergers & Acquisitions, Expansion Plans

4 Market Size by Type
4.1 Global Bupivacaine Liposome Injectable Suspension Historic Market Review by Type (2015-2020)
4.1.2 Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Type (2015-2020)
4.1.3 Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Type (2015-2020)
4.1.4 Bupivacaine Liposome Injectable Suspension Price by Type (2015-2020)
4.1 Global Bupivacaine Liposome Injectable Suspension Market Estimates and Forecasts by Type (2021-2026)
4.2.2 Global Bupivacaine Liposome Injectable Suspension Sales Forecast by Type (2021-2026)
4.2.3 Global Bupivacaine Liposome Injectable Suspension Revenue Forecast by Type (2021-2026)
4.2.4 Bupivacaine Liposome Injectable Suspension Price Forecast by Type (2021-2026)

5 Global Bupivacaine Liposome Injectable Suspension Market Size by Application
5.1 Global Bupivacaine Liposome Injectable Suspension Historic Market Review by Application (2015-2020)
5.1.2 Global Bupivacaine Liposome Injectable Suspension Sales Market Share by Application (2015-2020)
5.1.3 Global Bupivacaine Liposome Injectable Suspension Revenue Market Share by Application (2015-2020)
5.1.4 Bupivacaine Liposome Injectable Suspension Price by Application (2015-2020)
5.2 Global Bupivacaine Liposome Injectable Suspension Market Estimates and Forecasts by Application (2021-2026)
5.2.2 Global Bupivacaine Liposome Injectable Suspension Sales Forecast by Application (2021-2026)
5.2.3 Global Bupivacaine Liposome Injectable Suspension Revenue Forecast by Application (2021-2026)
5.2.4 Bupivacaine Liposome Injectable Suspension Price Forecast by Application (2021-2026)

6 North America
6.1 North America Bupivacaine Liposome Injectable Suspension Breakdown Data by Company
6.2 North America Bupivacaine Liposome Injectable Suspension Breakdown Data by Type
6.3 North America Bupivacaine Liposome Injectable Suspension Breakdown Data by Application
6.4 North America Bupivacaine Liposome Injectable Suspension Breakdown Data by Countries
6.4.1 North America Bupivacaine Liposome Injectable Suspension Sales by Countries
6.4.2 North America Bupivacaine Liposome Injectable Suspension Revenue by Countries
6.4.3 U.S.
6.4.4 Canada

7 Europe
7.1 Europe Bupivacaine Liposome Injectable Suspension Breakdown Data by Company
7.2 Europe Bupivacaine Liposome Injectable Suspension Breakdown Data by Type
7.3 Europe Bupivacaine Liposome Injectable Suspension Breakdown Data by Application
7.4 Europe Bupivacaine Liposome Injectable Suspension Breakdown Data by Countries
7.4.1 Europe Bupivacaine Liposome Injectable Suspension Sales by Countries
7.4.2 Europe Bupivacaine Liposome Injectable Suspension Revenue by Countries
7.4.3 Germany
7.4.4 France
7.4.5 U.K.
7.4.6 Italy
7.4.7 Russia

8 Asia Pacific
8.1 Asia Pacific Bupivacaine Liposome Injectable Suspension Breakdown Data by Company
8.2 Asia Pacific Bupivacaine Liposome Injectable Suspension Breakdown Data by Type
8.3 Asia Pacific Bupivacaine Liposome Injectable Suspension Breakdown Data by Application
8.4 Asia Pacific Bupivacaine Liposome Injectable Suspension Breakdown Data by Regions
8.4.1 Asia Pacific Bupivacaine Liposome Injectable Suspension Sales by Regions
8.4.2 Asia Pacific Bupivacaine Liposome Injectable Suspension Revenue by Regions
8.4.3 China
8.4.4 Japan
8.4.5 South Korea
8.4.6 India
8.4.7 Australia
8.4.8 Taiwan
8.4.9 Indonesia
8.4.10 Thailand
8.4.11 Malaysia
8.4.12 Philippines
8.4.13 Vietnam

9 Latin America
9.1 Latin America Bupivacaine Liposome Injectable Suspension Breakdown Data by Company
9.2 Latin America Bupivacaine Liposome Injectable Suspension Breakdown Data by Type
9.3 Latin America Bupivacaine Liposome Injectable Suspension Breakdown Data by Application
9.4 Latin America Bupivacaine Liposome Injectable Suspension Breakdown Data by Countries
9.4.1 Latin America Bupivacaine Liposome Injectable Suspension Sales by Countries
9.4.2 Latin America Bupivacaine Liposome Injectable Suspension Revenue by Countries
9.4.3 Mexico
9.4.4 Brazil
9.4.5 Argentina

10 Middle East and Africa
10.1 Middle East and Africa Bupivacaine Liposome Injectable Suspension Breakdown Data by Type
10.2 Middle East and Africa Bupivacaine Liposome Injectable Suspension Breakdown Data by Application
10.3 Middle East and Africa Bupivacaine Liposome Injectable Suspension Breakdown Data by Countries
10.3.1 Middle East and Africa Bupivacaine Liposome Injectable Suspension Sales by Countries
10.3.2 Middle East and Africa Bupivacaine Liposome Injectable Suspension Revenue by Countries
10.3.3 Turkey
10.3.4 Saudi Arabia
10.3.5 U.A.E

11 Company Profiles
11.1 Pacira Pharmaceuticals
11.1.1 Pacira Pharmaceuticals Corporation Information
11.1.2 Pacira Pharmaceuticals Business Overview and Total Revenue (2019 VS 2018)
11.1.3 Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Sales, Revenue, Average Selling Price (ASP) and Gross Margin (2015-2020)
11.1.4 Pacira Pharmaceuticals Bupivacaine Liposome Injectable Suspension Products and Services
11.1.5 Pacira Pharmaceuticals SWOT Analysis
11.1.6 Pacira Pharmaceuticals Recent Developments

12 Supply Chain and Sales Channels Analysis
12.1 Supply Chain Analysis
12.2 Sales Channels Analysis
12.2.1 Bupivacaine Liposome Injectable Suspension Sales Channels
12.2.2 Bupivacaine Liposome Injectable Suspension Distributors
12.3 Bupivacaine Liposome Injectable Suspension Customers

13 Estimates and Projections by Regions (2021-2026)
13.1 Global Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.1.1 Global Bupivacaine Liposome Injectable Suspension Sales Forecast by Regions (2021-2026)
13.1.2 Global Bupivacaine Liposome Injectable Suspension Revenue Forecast by Regions (2021-2026)
13.2 North America Market Size Forecast (2021-2026)
13.2.1 North America Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.2.2 North America Bupivacaine Liposome Injectable Suspension Revenue Forecast (2021-2026)
13.2.3 North America Bupivacaine Liposome Injectable Suspension Size Forecast by County (2021-2026)
13.3 Europe Market Size Forecast (2021-2026)
13.3.1 Europe Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.3.2 Europe Bupivacaine Liposome Injectable Suspension Revenue Forecast (2021-2026)
13.3.3 Europe Bupivacaine Liposome Injectable Suspension Size Forecast by County (2021-2026)
13.4 Asia Pacific Market Size Forecast (2021-2026)
13.4.1 Asia Pacific Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.4.2 Asia Pacific Bupivacaine Liposome Injectable Suspension Revenue Forecast (2021-2026)
13.4.3 Asia Pacific Bupivacaine Liposome Injectable Suspension Size Forecast by Region (2021-2026)
13.5 Latin America Market Size Forecast (2021-2026)
13.5.1 Latin America Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.5.2 Latin America Bupivacaine Liposome Injectable Suspension Revenue Forecast (2021-2026)
13.5.3 Latin America Bupivacaine Liposome Injectable Suspension Size Forecast by County (2021-2026)
13.6 Middle East and Africa Market Forecast
13.6.1 Middle East and Africa Bupivacaine Liposome Injectable Suspension Sales Forecast (2021-2026)
13.6.2 Middle East and Africa Bupivacaine Liposome Injectable Suspension Revenue Forecast (2021-2026)
13.6.3 Middle East and Africa Bupivacaine Liposome Injectable Suspension Size Forecast by County (2021-2026)

14 Research Findings and Conclusion

15 Appendix
15.1 Research Methodology
15.1.1 Methodology/Research Approach
15.1.2 Data Source
15.2 Author Details
15.3 Disclaimer

...

【掲載企業】

Pacira Pharmaceuticals

【免責事項】
https://www.globalresearch.jp/disclaimer

★リサーチレポート[ ブピバカインリポソーム注射懸濁液の世界市場2020-2026:20ml、10ml(Global Bupivacaine Liposome Injectable Suspension Industry Research Report, Growth Trends and Competitive Analysis 2020-2026)]についてメールでお問い合わせはこちらでお願いします。